pyrroles has been researched along with Kidney Diseases in 70 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 7 (10.00) | 18.7374 |
| 1990's | 3 (4.29) | 18.2507 |
| 2000's | 23 (32.86) | 29.6817 |
| 2010's | 36 (51.43) | 24.3611 |
| 2020's | 1 (1.43) | 2.80 |
| Authors | Studies |
|---|---|
| Abe, M; Endo, M; Fukuda, N; Horikoshi, S; Inoue, T; Mineshige, T; Otsuki, M; Otsuki, T | 1 |
| El-Kashef, DH; Makled, MN | 1 |
| Bayliss, G; Guan, Y; Liu, L; Masucci, MV; Xiong, C; Zhang, W; Zhang, Y; Zhao, TC; Zhou, X; Zhuang, MA; Zhuang, S | 1 |
| Boy, M; Chan, G; Chow, V; Krishnaswami, S; Wang, C | 1 |
| Bossart, W; Etter, A; Fehr, T; Hässig, A; Müller, N; Roos, M; Schiesser, M; Wüthrich, RP | 1 |
| El-Moselhy, MA; El-Sheikh, AA | 1 |
| Aksakal, E; Ekinci, M; Işik, T; Kaya, A; Kaya, Y; Kurt, M; Sevimli, S; Tanboğa, IH; Topçu, S | 1 |
| Chatterjee, P; Kumar, R; Sikka, K | 1 |
| Campese, VM | 1 |
| Arévalo, M; Docherty, NG; Eleno, N; Fuentes-Calvo, I; Grande, MT; López-Novoa, JM; Pérez-Barriocanal, F; Rodríguez-Peña, AB | 1 |
| Aslani, P; Ayoub, R; Gelissen, IC; Moles, R; Nguyen, HL; Tiao, DK | 1 |
| Ziaie, S | 1 |
| Dawani, ML; Mahboob, T; Yasmeen, G | 1 |
| Charbit, D; Defortescu, G; Di Fiore, F; Giwerc, A; Gouerant, S; Nouhaud, FX; Pfister, C; Sabourin, JC | 1 |
| Baelde, HJ; Clahsen-van Groningen, MC; Danser, AH; Hansen, A; Kappers, MH; Lankhorst, S; Mathijssen, RH; Sleijfer, S; Smedts, FM; van den Meiracker, AH | 1 |
| Baelde, HJ; Clahsen-van Groningen, MC; Danser, AH; Lankhorst, S; Smedts, FM; van den Meiracker, AH | 1 |
| Albiges, L; Ficarra, V; Heng, DY; Hsieh, JJ; Larkin, J; Purdue, MP; Schmidinger, M; Signoretti, S; Swanton, C | 1 |
| Adánez, G; Ayala, I; Castells, MT; García Pérez, B; Martín Castillo, A; Montes, A; Sánchez-Polo, MT | 1 |
| Stergiopoulos, K; Wu, S; Zhu, X | 1 |
| Campese, VM; Ku, E; Nobakht, N | 1 |
| Chen, HX; Cleck, JN | 1 |
| Jin, YZ; Min, R; Wang, Q; Zhang, XY; Zhou, X | 1 |
| Berger, M; Krane, V; Lilienthal, J; Schambeck, C; Wanner, C; Winkler, K | 1 |
| Ando, D; Hirawa, N; Umemura, S; Yasuda, G | 1 |
| Melfi, R; Nusca, A; Patti, G; Sciascio, GD | 1 |
| Acikel, S; Aydinalp, A; Bal, U; Bayraktar, N; Muderrisoglu, H; Ozin, B; Sade, E; Yildirir, A | 1 |
| Amato, M; Bellandi, F; Gallopin, M; Leoncini, M; Maioli, M; Tedeschi, D; Toso, A | 1 |
| Patti, G | 1 |
| Colonna, G; D'Ambrosio, A; Di Sciascio, G; Montinaro, A; Nusca, A; Pasceri, V; Patti, G; Ricottini, E | 1 |
| Harbord, N | 1 |
| Sadat, U | 1 |
| Cheng, QL; Ye, P; Zhao, JH | 1 |
| Takagi, H; Umemoto, T | 2 |
| Teramoto, T | 1 |
| Dolman, ME; Harmsen, S; Hennink, WE; Kéri, G; Kok, RJ; Lacombe, M; Orfi, L; Pieters, EH; Sparidans, RW; Storm, G; Szokol, B | 1 |
| Vincenti, F | 1 |
| Arias, SC; Camara, NO; Fanelli, C; Fujihara, CK; Kuriki, PS; Machado, FG; Malheiros, DM; Zatz, R | 1 |
| Fan, W; Fu, X; Geng, W; Gu, X; Hao, G; Jiang, Y; Li, S; Li, W; Li, X; Wang, X; Wang, Y; Wu, W; Yang, Z | 1 |
| Fujita, T; Fuke, Y; Fukuda, N; Kajiwara, M; Kitai, M; Matsuda, H; Matsumoto, K; Matsumoto, Y; Ra, C; Shimokawa, T; Soma, M; Tsunemi, A; Ueno, T | 1 |
| Cao, S; Cui, K; Hou, Y; Wang, P; Zhang, L | 1 |
| Hayashi, M; Hayashida, R; Ishii, H; Jinno, Y; Murohara, T; Okada, K; Okumura, S; Sakakibara, M; Tanaka, A | 1 |
| Bianchi, S; Bigazzi, R; Caiazza, A; Campese, VM | 1 |
| Ravnskov, U | 1 |
| ARATO, M; BUDA, B; KELENYI, G; ORBAN, I | 1 |
| HULUBEI, P; MIHAI, C; OANCEA, C | 1 |
| Cressman, MD; Harris, S; Hutchinson, HG; Pears, JS; Vidt, DG | 1 |
| Asano, T; Hayakawa, M; Kosaka, T; Miyajima, A; Mizuguchi, Y | 1 |
| Ayame, H; Bando, T; Fukuda, N; Matsuda, H; Matsumoto, K; Mugishima, H; Saito, S; Serie, K; Sugiyama, H; Tahira, Y; Ueno, T; Zhang, W | 1 |
| Fukuda, N | 1 |
| Hey-Hadavi, JH; Kuntze, E; Lepetri, B; Luo, D; Pittman, D; Silverman, P | 1 |
| Demova, H; Kluckova, H; Komers, R; Lecian, D; Lodererova, A; Teplan, V; Voska, L; Zdychova, J | 1 |
| Kiberd, BA | 1 |
| Chiesa, G; Cippone, V; Conte Camerino, D; De Luca, A; De Vito, D; Didonna, MP; Frigeri, A; Nicchia, GP; Pierno, S; Pisoni, M; Rizzo, C; Scanziani, E; Sirtori, C; Svelto, M | 1 |
| Abad, S; Cachofeiro, V; de Vinuesa, SG; Goicoechea, M; Gómez-Campderá, F; Lahera, V; Luño, J; Vega, A | 1 |
| Coombes, JS; Fassett, RG; Oliver, KR; Summers, MJ | 1 |
| Hosoya, T; Kawamoto, S; Kawamura, T; Miyazaki, Y | 1 |
| Bittner, V; Breazna, A; Deedwania, P; Dobson, S; Kastelein, JJ; Shepherd, J; Wenger, NK; Wilson, DJ; Zuckerman, A | 1 |
| Campese, VM; Park, J | 1 |
| Paraskevas, KI | 1 |
| Chello, M; D'Ambrosio, A; Di Sciascio, G; Nusca, A; Pasceri, V; Patti, G; Vetrovec, GW | 1 |
| He, J; McCarter, RJ; Moudgil, A; Sgambat, K | 1 |
| Chimata, M; Kakuta, S; Nagase, M; Shimomura, M; Suzuki, Y | 1 |
| Cao, Z; Cooper, ME; Cox, AJ; Gilbert, RE; Jandeleit-Dahm, K; Kelly, DJ | 1 |
| Borsa-Lebas, F; Etienne, I; Fillastre, JP; Humbert, G; Leroy, A | 1 |
| Debusmann, ER; Gassmann, M; Irmisch, R; Kindler, J; Koch, KM; Lahn, W; Pujadas, JO; Ritz, E; Schunkert, H; Sieberth, HG | 1 |
| Hirschfeld, DR; Maloney, PJ; Martinez, GR; Rosenkranz, RP; Walker, KA; Yang, DS | 1 |
| Ford, EJ | 1 |
| Iwanow, ED | 1 |
| Gibson, SL; Goldberg, A; Mackenzie, JC | 1 |
16 review(s) available for pyrroles and Kidney Diseases
| Article | Year |
|---|---|
Dyslipidemia and progression of kidney disease: role of lipid-lowering drugs.
Topics: Acute Kidney Injury; Atorvastatin; Disease Progression; Dyslipidemias; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Kidney; Kidney Diseases; Male; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Renal Insufficiency, Chronic; Rosuvastatin Calcium; Sulfonamides | 2014 |
Renal cell carcinoma.
Topics: Axitinib; Bevacizumab; Carcinoma, Renal Cell; Humans; Imidazoles; Indazoles; Indoles; Kidney; Kidney Diseases; Niacinamide; Phenylurea Compounds; Pyrimidines; Pyrroles; Quality of Life; Risk Factors; Sorafenib; Sulfonamides; Sunitinib; Vascular Endothelial Growth Factor A | 2017 |
Risk of hypertension and renal dysfunction with an angiogenesis inhibitor sunitinib: systematic review and meta-analysis.
Topics: Angiogenesis Inhibitors; Carcinoma, Renal Cell; Gastrointestinal Stromal Tumors; Humans; Hypertension; Indoles; Kidney Diseases; Kidney Neoplasms; Protein Kinase Inhibitors; Pyrroles; Sunitinib | 2009 |
Lixivaptan: a novel vasopressin receptor antagonist.
Topics: Animals; Antidiuretic Hormone Receptor Antagonists; Azepines; Benzamides; Clinical Trials, Phase III as Topic; Heart Failure; Humans; Kidney Diseases; Pyrroles; Receptors, Vasopressin | 2009 |
Adverse effects of anticancer agents that target the VEGF pathway.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Brain Diseases; Capillary Leak Syndrome; Cardiovascular Diseases; Clinical Trials as Topic; Drug Delivery Systems; Drug Interactions; Forecasting; Gastrointestinal Diseases; Hemorrhage; Humans; Indoles; Kidney Diseases; Neoplasm Proteins; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Risk Factors; Sorafenib; Sunitinib; Vascular Endothelial Growth Factor A; Wound Healing | 2009 |
Statin loading before percutaneous coronary intervention: proposed mechanisms and applications.
Topics: Angioplasty, Balloon, Coronary; Anticholesteremic Agents; Atorvastatin; Biomarkers, Pharmacological; Confidence Intervals; Endothelium, Vascular; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Inflammation; Kidney Diseases; Multivariate Analysis; Myocardial Infarction; Pyrimidines; Pyrroles; Risk Factors; Rosuvastatin Calcium; Sulfonamides; Time Factors | 2010 |
Novel nephrotoxins.
Topics: Adenine; Alcohols; Angiogenesis Inhibitors; Anticonvulsants; Antipsychotic Agents; Dasatinib; Diphosphonates; Glutamates; Guanine; HIV Protease Inhibitors; Humans; Indoles; Kidney Diseases; Organophosphonates; Oxalates; Pamidronate; Pemetrexed; Phenindione; Plants, Toxic; Proton Pump Inhibitors; Pyrimidines; Pyrroles; Selective Serotonin Reuptake Inhibitors; Sunitinib; Tenofovir; Thiazoles; Triazines | 2011 |
Contrast-induced nephropathy: do statins offer protection?
Topics: Amidohydrolases; Atorvastatin; Contrast Media; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney Diseases; Pyrroles; Randomized Controlled Trials as Topic | 2011 |
A meta-analysis of randomized trials for effects of atorvastatin on renal function in chronic kidney disease.
Topics: Atorvastatin; Chronic Disease; Glomerular Filtration Rate; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney Diseases; Pyrroles; Randomized Controlled Trials as Topic | 2011 |
A meta-analysis of randomized trials for effects of periprocedural atorvastatin on contrast-induced nephropathy.
Topics: Atorvastatin; Contrast Media; Heptanoic Acids; Humans; Kidney Diseases; Pyrroles; Randomized Controlled Trials as Topic; Treatment Outcome | 2011 |
Pitavastatin: clinical effects from the LIVES Study.
Topics: Atorvastatin; Biomarkers; Cardiovascular Diseases; Cerebrovascular Disorders; Cholesterol, HDL; Cholesterol, LDL; Clinical Trials, Phase IV as Topic; Comorbidity; Diabetes Mellitus, Type 2; Dyslipidemias; Glomerular Filtration Rate; Glycated Hemoglobin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Japan; Kidney Diseases; Multicenter Studies as Topic; Muscular Diseases; Prospective Studies; Pyrroles; Quinolines; Risk; Simvastatin; Treatment Outcome; Triglycerides | 2011 |
Are calcineurin inhibitors-free regimens ready for prime time?
Topics: Abatacept; Calcineurin Inhibitors; Drug Therapy, Combination; Graft Rejection; Graft Survival; Humans; Immunoconjugates; Immunosuppressive Agents; Kidney Diseases; Piperidines; Pyrimidines; Pyrroles; Time Factors; Treatment Outcome | 2012 |
Rosuvastatin-induced arrest in progression of renal disease.
Topics: Aged; Atorvastatin; Controlled Clinical Trials as Topic; Creatine; Disease Progression; Drug Administration Schedule; Female; Fluorobenzenes; Glomerular Filtration Rate; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Kidney; Kidney Diseases; Male; Middle Aged; Pravastatin; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2004 |
Tolerability of atorvastatin in a population aged > or =65 years: a retrospective pooled analysis of results from fifty randomized clinical trials.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Chemical and Drug Induced Liver Injury; Dose-Response Relationship, Drug; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Kidney Diseases; Male; Musculoskeletal Diseases; Pyrroles; Randomized Controlled Trials as Topic; Retrospective Studies | 2006 |
Statin therapy in peritoneal dialysis patients: effects beyond lipid lowering.
Topics: Anticholesteremic Agents; Atorvastatin; C-Reactive Protein; Chronic Disease; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertriglyceridemia; Kidney Diseases; Lipids; Peritoneal Dialysis; Pyrroles; Risk Assessment; Risk Factors; Survival Rate; Treatment Outcome | 2008 |
Role of hyperlipidemia in progressive renal disease: focus on diabetic nephropathy.
Topics: Animals; Anticholesteremic Agents; Atorvastatin; Clinical Trials as Topic; Diabetic Nephropathies; Disease Progression; Gene Expression; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; In Situ Hybridization; Kidney Diseases; Kidney Glomerulus; Lovastatin; Male; Nephrectomy; Pravastatin; Pyrroles; Rats; Rats, Sprague-Dawley; Simvastatin; Transforming Growth Factor beta | 1999 |
13 trial(s) available for pyrroles and Kidney Diseases
| Article | Year |
|---|---|
Rosuvastatin versus atorvastatin to prevent contrast induced nephropathy in patients undergoing primary percutaneous coronary intervention (ROSA-cIN trial).
Topics: Atorvastatin; Contrast Media; Coronary Angiography; Dose-Response Relationship, Drug; Electrocardiography; Female; Fluorobenzenes; Follow-Up Studies; Glomerular Filtration Rate; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Kidney; Kidney Diseases; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Pyrimidines; Pyrroles; Retrospective Studies; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome; Turkey | 2013 |
Association of high-density lipoprotein cholesterol with improvement of endothelial dysfunction recovery in renovascular disease.
Topics: Adult; Atorvastatin; Biomarkers; Cholesterol, HDL; Delayed-Action Preparations; Drug Therapy, Combination; Endothelium, Vascular; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Ischemia; Kidney Diseases; Male; Middle Aged; Niacin; Nitrates; Pakistan; Pyrroles; Recovery of Function; Renal Artery; Time Factors; Treatment Outcome; Ultrasonography, Doppler | 2015 |
[Efficacy of high dose atorvastatin on preventing contrast induced nephropathy in patients underwent coronary angiography].
Topics: Aged; Atorvastatin; Contrast Media; Coronary Angiography; Female; Heptanoic Acids; Humans; Kidney Diseases; Kidney Failure, Chronic; Male; Middle Aged; Pyrroles | 2009 |
Antibodies to platelet factor 4-heparin complex and outcome in hemodialysis patients with diabetes.
Topics: Aged; Antibodies; Aspirin; Atorvastatin; Cause of Death; Chi-Square Distribution; Death, Sudden; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Germany; Heparin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kaplan-Meier Estimate; Kidney Diseases; Logistic Models; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Platelet Factor 4; Proportional Hazards Models; Prospective Studies; Pyrroles; Renal Dialysis; Risk Assessment; Risk Factors; Stroke; Time Factors; Treatment Outcome | 2010 |
Effects of atorvastatin versus probucol on low-density lipoprotein subtype distribution and renal function in hyperlipidemic patients with nondiabetic nephropathy.
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Cross-Over Studies; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Kidney Diseases; Lipoproteins, LDL; Male; Middle Aged; Particle Size; Probucol; Prospective Studies; Pyrroles; Young Adult | 2010 |
Prevention of contrast-induced impairment of renal function by short-term or long-term statin therapy in patients undergoing elective coronary angiography.
Topics: Atorvastatin; Contrast Media; Coronary Angiography; Creatinine; Female; Glomerular Filtration Rate; Heptanoic Acids; Humans; Kidney Diseases; Kidney Function Tests; Male; Middle Aged; Prospective Studies; Pyrroles | 2010 |
Short-term, high-dose Atorvastatin pretreatment to prevent contrast-induced nephropathy in patients with acute coronary syndromes undergoing percutaneous coronary intervention (from the ARMYDA-CIN [atorvastatin for reduction of myocardial damage during an
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Atorvastatin; Contrast Media; Coronary Angiography; Creatinine; Dose-Response Relationship, Drug; Double-Blind Method; Electrocardiography; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney Diseases; Kidney Function Tests; Male; Prospective Studies; Pyrroles; Time Factors; Treatment Outcome | 2011 |
Beneficial effects of high-dose atorvastatin pretreatment on renal function in patients with acute ST-segment elevation myocardial infarction undergoing emergency percutaneous coronary intervention.
Topics: Aged; Angioplasty, Balloon, Coronary; Atorvastatin; Contrast Media; Creatinine; Cystatin C; Emergency Treatment; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney Diseases; Kidney Function Tests; Male; Myocardial Infarction; Pyrroles | 2012 |
[Atorvastatin prevents contrast agent-induced renal injury in patients undergoing coronary angiography by inhibiting oxidative stress].
Topics: Aged; Atorvastatin; Contrast Media; Coronary Angiography; Female; Heptanoic Acids; Humans; Kidney Diseases; Male; Middle Aged; Oxidative Stress; Pyrroles | 2012 |
A controlled, prospective study of the effects of atorvastatin on proteinuria and progression of kidney disease.
Topics: Anticholesteremic Agents; Atorvastatin; Chronic Disease; Disease Progression; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Kidney Diseases; Kidney Glomerulus; Male; Middle Aged; Prospective Studies; Proteinuria; Pyrroles | 2003 |
Effects of atorvastatin on inflammatory and fibrinolytic parameters in patients with chronic kidney disease.
Topics: Aged; Aged, 80 and over; Atorvastatin; C-Reactive Protein; Cardiovascular Diseases; Chronic Disease; Dose-Response Relationship, Drug; Dyslipidemias; Female; Fibrinogen; Fibrinolysis; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Interleukin-6; Kidney Diseases; Lipid Metabolism; Male; Middle Aged; Plasminogen Activator Inhibitor 1; Prospective Studies; Pyrroles; Tissue Plasminogen Activator | 2006 |
Effect of atorvastatin on cognitive function in patients from the Lipid Lowering and Onset of Renal Disease (LORD) trial.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Cognition; Double-Blind Method; Female; Heptanoic Acids; Humans; Kidney Diseases; Lipids; Male; Middle Aged; Neuropsychological Tests; Placebos; Predictive Value of Tests; Pyrroles; Regression Analysis | 2007 |
Effect of intensive lipid lowering with atorvastatin on renal function in patients with coronary heart disease: the Treating to New Targets (TNT) study.
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Blood Pressure; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Double-Blind Method; Female; Glomerular Filtration Rate; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney; Kidney Diseases; Male; Middle Aged; Pyrroles | 2007 |
41 other study(ies) available for pyrroles and Kidney Diseases
| Article | Year |
|---|---|
Preclinical Study of DNA-Recognized Peptide Compound Pyrrole-Imidazole Polyamide Targeting Human TGF-β1 Promoter for Progressive Renal Diseases in the Common Marmoset.
Topics: Animals; Base Sequence; Cadherins; Callithrix; Cyclosporine; DNA; Fibrosis; Humans; Imidazoles; Kidney; Kidney Diseases; Nylons; Peptides; Promoter Regions, Genetic; Pyrroles; RNA, Messenger; Snail Family Transcription Factors; Transforming Growth Factor beta1; Urethral Obstruction | 2019 |
Saroglitazar attenuates renal fibrosis induced by unilateral ureteral obstruction via inhibiting TGF-β/Smad signaling pathway.
Topics: Animals; Anti-Inflammatory Agents; Antioxidants; Fibrosis; Inflammation; Kidney Diseases; Male; Oxidative Stress; Phenylpropionates; PPAR alpha; PPAR gamma; Pyrroles; Rats; Rats, Sprague-Dawley; Signal Transduction; Smad3 Protein; Transforming Growth Factor beta1; Ureteral Obstruction | 2020 |
Selective inhibition of class IIa histone deacetylases alleviates renal fibrosis.
Topics: Animals; Bone Morphogenetic Protein 7; Cell Line, Transformed; Fibrosis; Histone Deacetylase Inhibitors; Histone Deacetylases; Hydroxamic Acids; Kidney Diseases; Male; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Mice; Pyrroles; Smad7 Protein; Transforming Growth Factor beta1; Ureteral Obstruction | 2019 |
Pharmacokinetics of tofacitinib, a janus kinase inhibitor, in patients with impaired renal function and end-stage renal disease.
Topics: Adult; Aged; Area Under Curve; Aryl Hydrocarbon Hydroxylases; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP3A; Female; Half-Life; Humans; Janus Kinases; Kidney Diseases; Kidney Failure, Chronic; Liver; Male; Middle Aged; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Renal Dialysis | 2014 |
Association of BK viremia with human leukocyte antigen mismatches and acute rejection, but not with type of calcineurin inhibitor.
Topics: Adult; Aged; Allografts; Antibodies, Monoclonal; Azathioprine; Basiliximab; BK Virus; Cohort Studies; Cyclosporine; Female; Glomerular Filtration Rate; Graft Rejection; Histocompatibility; HLA Antigens; Humans; Immunosuppressive Agents; Kidney Diseases; Kidney Transplantation; Logistic Models; Male; Middle Aged; Multivariate Analysis; Mycophenolic Acid; Polyomavirus Infections; Proteinuria; Pyrroles; Quinazolines; Recombinant Fusion Proteins; Tacrolimus; Tumor Virus Infections; Viremia | 2014 |
Protective mechanisms of atorvastatin against doxorubicin-induced hepato-renal toxicity.
Topics: Animals; Anti-Inflammatory Agents; Antibiotics, Antineoplastic; Antioxidants; Apoptosis; Atorvastatin; Chemical and Drug Induced Liver Injury; Down-Regulation; Doxorubicin; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney Diseases; Male; Nitric Oxide; Oxidative Stress; Pyrroles; Rats; Rats, Wistar; Up-Regulation | 2014 |
Nephrogenic epistaxis.
Topics: Adult; Carcinoma, Renal Cell; Chemoradiotherapy; Diagnosis, Differential; Epistaxis; Humans; Indoles; Kidney Diseases; Male; Neoplasm Metastasis; Nose; Nose Neoplasms; Positron-Emission Tomography; Pyrroles; Recurrence; Sunitinib; Tomography, X-Ray Computed | 2014 |
Effect of angiotensin II and small GTPase Ras signaling pathway inhibition on early renal changes in a murine model of obstructive nephropathy.
Topics: Angiotensin II; Animals; Atorvastatin; Disease Models, Animal; Fibrosis; Heptanoic Acids; Humans; Kidney; Kidney Diseases; Mice; Monomeric GTP-Binding Proteins; Pyrroles; Receptor, Angiotensin, Type 1; Signal Transduction; Ureteral Obstruction | 2014 |
Statin use in Australian children: a retrospective audit of four pediatric hospitals.
Topics: Adolescent; Atorvastatin; Australia; Child; Child, Preschool; Drug Utilization Review; Fluorobenzenes; Heptanoic Acids; Hospitals, Pediatric; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Infant; Kidney Diseases; Organ Transplantation; Pravastatin; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2014 |
Role of high-density lipoprotein cholesterol in renovascular disease treatment.
Topics: Cholesterol, HDL; Endothelium, Vascular; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Ischemia; Kidney Diseases; Male; Pyrroles; Renal Artery | 2015 |
Baseline chronic kidney disease is associated with toxicity and survival in patients treated with targeted therapies for metastatic renal cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Chronic Disease; Female; Glomerular Filtration Rate; Humans; Indoles; Kidney Diseases; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyrroles; Retrospective Studies; Sirolimus; Sorafenib; Sunitinib; Survival Rate | 2015 |
Greater Sensitivity of Blood Pressure Than Renal Toxicity to Tyrosine Kinase Receptor Inhibition With Sunitinib.
Topics: Animals; Antineoplastic Agents; Blood Pressure; Dose-Response Relationship, Drug; Indoles; Kidney; Kidney Diseases; Male; Podocytes; Protein Kinase Inhibitors; Pyrroles; Rats; Rats, Inbred WKY; Sunitinib; Vascular Endothelial Growth Factor A | 2015 |
Effect of high salt diet on blood pressure and renal damage during vascular endothelial growth factor inhibition with sunitinib.
Topics: Angiogenesis Inhibitors; Animals; Blood Pressure; Indoles; Kidney Diseases; Male; Pyrroles; Rats; Rats, Inbred WKY; Sodium Chloride, Dietary; Sunitinib; Vascular Endothelial Growth Factor A | 2016 |
Effects of atorvastatin on progression-regression of renal injury in hyperlipidemic chickens.
Topics: Animals; Anticholesteremic Agents; Atorvastatin; Chickens; Disease Models, Animal; Disease Progression; Drug Administration Schedule; Heptanoic Acids; Hyperlipidemias; Kidney Diseases; Kidney Glomerulus; Kidney Tubules; Lipids; Male; Pyrroles | 2008 |
Short-term high-dose atorvastatin for periprocedural myocardial infarction prevention in patients with renal dysfunction.
Topics: Aged; Aged, 80 and over; Analysis of Variance; Angioplasty, Balloon, Coronary; Atorvastatin; Biomarkers; Chi-Square Distribution; Coronary Angiography; Coronary Artery Disease; Creatine Kinase, MB Form; Creatinine; Drug Administration Schedule; Female; Glomerular Filtration Rate; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Italy; Kidney Diseases; Logistic Models; Male; Myocardial Infarction; Odds Ratio; Pyrroles; Randomized Controlled Trials as Topic; Retrospective Studies; Risk Assessment; Risk Factors; Time Factors; Treatment Outcome; Up-Regulation | 2011 |
Short-term high-dose atorvastatin for periprocedural myocardial infarction prevention in patients with renal dysfunction.
Topics: Angioplasty, Balloon, Coronary; Atorvastatin; Biomarkers; Coronary Angiography; Coronary Artery Disease; Creatine Kinase, MB Form; Creatinine; Drug Administration Schedule; Evidence-Based Medicine; Glomerular Filtration Rate; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney Diseases; Myocardial Infarction; Pyrroles; Risk Assessment; Risk Factors; Time Factors; Treatment Outcome; Up-Regulation | 2011 |
[The effects of atorvastatin on aging kidney].
Topics: Aging; Animals; Anticholesteremic Agents; Arteriosclerosis; Atorvastatin; Female; Heptanoic Acids; Kidney; Kidney Diseases; Pyrroles; Rats; Rats, Wistar; Renal Artery | 2011 |
Targeting of a platinum-bound sunitinib analog to renal proximal tubular cells.
Topics: Animals; Area Under Curve; Cell Line; Cell Survival; Drug Carriers; Drug Delivery Systems; Fibrosis; Humans; Immunohistochemistry; Indoles; Kidney; Kidney Diseases; Kidney Tubules, Proximal; Male; Mice; Mice, Inbred C57BL; Muramidase; Organoplatinum Compounds; Protein-Tyrosine Kinases; Pyrroles; Receptor, Platelet-Derived Growth Factor beta; Sunitinib | 2012 |
Chronic VEGF blockade worsens glomerular injury in the remnant kidney model.
Topics: Animals; Catheter Ablation; Glomerulosclerosis, Focal Segmental; Indoles; Kidney Diseases; Kidney Glomerulus; Male; Pyrroles; Rats; Rats, Wistar; Sunitinib; Vascular Endothelial Growth Factor A | 2012 |
Development of pyrrole-imidazole polyamide targeting fc receptor common gamma chain for the treatment of immune-complex related renal disease.
Topics: Animals; Cell Line; Cells, Cultured; Gene Expression Regulation; Imidazoles; Immune Complex Diseases; Kidney Diseases; Leukocytes, Mononuclear; Male; Mice; Mice, Inbred C57BL; Nylons; Promoter Regions, Genetic; Pyrroles; Receptors, IgG; RNA, Messenger | 2012 |
Accelerated decline in renal function after acute myocardial infarction in patients with high low-density lipoprotein-cholesterol to high-density lipoprotein-cholesterol ratio.
Topics: Age Factors; Aged; Atorvastatin; Biomarkers; Body Mass Index; Cholesterol, HDL; Cholesterol, LDL; Creatinine; Disease Progression; Dyslipidemias; Female; Glomerular Filtration Rate; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney; Kidney Diseases; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Pyrroles; Retrospective Studies; Risk Factors; Time Factors; Treatment Outcome | 2014 |
ASCOT-LLA: questions about the benefits of atorvastatin.
Topics: Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Diabetes Mellitus; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney Diseases; Neoplasms; Pyrroles | 2003 |
[Studies on the excretion of prophobilinogen and aminolevulinic acid in patients with latent nephropathies].
Topics: Aminolevulinic Acid; Biological Transport; Body Fluids; Humans; Kidney Diseases; Pyrroles | 1960 |
[Clinical value of urinary pentdyopent and porphobilinogen in patients with hepatic and renal diseases].
Topics: Hemoglobins; Humans; Kidney Diseases; Liver Diseases; Porphobilinogen; Porphyrins; Pyrroles | 1963 |
Atorvastatin ameliorates renal tissue damage in unilateral ureteral obstruction.
Topics: Animals; Atorvastatin; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney; Kidney Diseases; Pyrroles; Rats; Rats, Sprague-Dawley; Transforming Growth Factor beta; Ureteral Obstruction | 2004 |
Development of gene silencing pyrrole-imidazole polyamide targeting the TGF-beta1 promoter for treatment of progressive renal diseases.
Topics: Animals; Cell Culture Techniques; Gene Silencing; Imidazoles; Kidney Diseases; Mesangial Cells; Nylons; Promoter Regions, Genetic; Pyrroles; Rats; Rats, Inbred Dahl; Rats, Wistar; RNA, Messenger; Transcription Factor AP-1; Transforming Growth Factor beta; Transforming Growth Factor beta1 | 2006 |
Development of gene therapies for cardiovascular and renal diseases by nucleic acid medicines.
Topics: Amides; Animals; Base Sequence; Cardiovascular Diseases; DNA, Antisense; Gene Silencing; Genetic Therapy; Hypertension, Renovascular; Imidazoles; Kidney Diseases; Male; Oligonucleotides, Antisense; Platelet-Derived Growth Factor; Promoter Regions, Genetic; Pyrroles; Rats; RNA, Catalytic; Swine; Transforming Growth Factor beta; Transforming Growth Factor beta1; Tunica Intima | 2006 |
Renal effects of HMG-CoA reductase inhibition in a rat model of chronic inhibition of nitric oxide synthesis.
Topics: Albuminuria; Analysis of Variance; Animals; Atorvastatin; Blood Pressure; Caveolin 1; Glomerular Filtration Rate; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Kidney Diseases; Kidney Glomerulus; Male; Models, Animal; NG-Nitroarginine Methyl Ester; Nitric Oxide; Pyrroles; Rats; Rats, Wistar; rhoA GTP-Binding Protein; Vascular Endothelial Growth Factor A | 2006 |
Atorvastatin has no beneficial effect on cardiovascular outcomes in patients with advanced chronic kidney disease.
Topics: Atorvastatin; Cardiovascular Diseases; Chronic Disease; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney Diseases; Pyrroles; Randomized Controlled Trials as Topic; Treatment Failure | 2006 |
Effects of chronic treatment with statins and fenofibrate on rat skeletal muscle: a biochemical, histological and electrophysiological study.
Topics: Action Potentials; Animals; Aquaporin 4; Atorvastatin; Body Weight; Chloride Channels; Dose-Response Relationship, Drug; Eating; Fatty Acids, Monounsaturated; Fenofibrate; Fluvastatin; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Indoles; Kidney Diseases; Lipids; Male; Membrane Potentials; Muscle Contraction; Muscle Fibers, Fast-Twitch; Muscle, Skeletal; Muscular Diseases; Myosin Heavy Chains; Organ Size; Pyrroles; Rats; Rats, Wistar; Rhabdomyolysis; Time Factors | 2006 |
[Effects of atorvastatin on hyperlipidemia in kidney disease patients].
Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Disease Progression; Drug Administration Schedule; Female; Heptanoic Acids; Humans; Hyperlipidemias; Kidney Diseases; Male; Middle Aged; Pyrroles; Renal Dialysis | 2007 |
HMG-CoA reductase inhibitors and renal function.
Topics: Anticholesteremic Agents; Atorvastatin; Chronic Disease; Coronary Disease; Glomerular Filtration Rate; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney; Kidney Diseases; Lipoproteins, LDL; Pyrroles | 2007 |
Usefulness of statin pretreatment to prevent contrast-induced nephropathy and to improve long-term outcome in patients undergoing percutaneous coronary intervention.
Topics: Aged; Angioplasty, Balloon, Coronary; Atorvastatin; Contrast Media; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney Diseases; Length of Stay; Male; Middle Aged; Multivariate Analysis; Pravastatin; Preoperative Care; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2008 |
Lipoprotein profile changes in children after renal transplantation in the modern immunosuppression era.
Topics: Adolescent; Adult; Atorvastatin; Child; Child, Preschool; Female; Heptanoic Acids; Humans; Immunosuppression Therapy; Immunosuppressive Agents; Kidney Diseases; Kidney Transplantation; Lipoproteins; Male; Prednisolone; Prevalence; Pyrroles | 2008 |
Pharmacokinetics of meropenem in patients with various degrees of renal function, including patients with end-stage renal disease.
Topics: Adult; Aged; Chromatography, High Pressure Liquid; Creatinine; Female; Humans; Infusions, Intravenous; Kidney Diseases; Kidney Failure, Chronic; Male; Meropenem; Middle Aged; Models, Biological; Pyrroles; Renal Dialysis; Thienamycins | 1993 |
Pharmacokinetics of meropenem (ICI 194,660) and its metabolite (ICI 213,689) in healthy subjects and in patients with renal impairment.
Topics: Adult; Humans; Kidney Diseases; Meropenem; Middle Aged; Pyrroles; Renal Dialysis; Thienamycins; Uremia | 1992 |
Pharmacokinetics of ramipril in hypertensive patients with renal insufficiency.
Topics: Adult; Aged; Antihypertensive Agents; Blood Pressure; Bridged Bicyclo Compounds; Bridged-Ring Compounds; Creatinine; Female; Humans; Hypertension, Renal; Kidney Diseases; Male; Middle Aged; Pyrroles; Ramipril | 1989 |
[(1H-imidazol-1-yl)methyl]- and [(3-pyridinyl)methyl]pyrroles as thromboxane synthetase inhibitors.
Topics: Animals; Aorta; Biological Availability; Blood Platelets; Chemical Phenomena; Chemistry; Humans; Imidazoles; Inflammation; Kidney Diseases; Male; Mice; Microsomes; Platelet Aggregation Inhibitors; Prostaglandin Endoperoxides, Synthetic; Prostaglandin H2; Prostaglandins H; Pyridines; Pyrroles; Rats; Structure-Activity Relationship; Swine; Thromboxane A2; Thromboxane B2; Thromboxane-A Synthase | 1989 |
Activity of gamma-glutamyl transpeptidase and other enzymes in the serum of sheep with liver or kidney damage.
Topics: Alcohol Oxidoreductases; Animals; Arginase; Aspartate Aminotransferases; Bilirubin; Brain; Carbon Tetrachloride Poisoning; Chemical and Drug Induced Liver Injury; Female; gamma-Glutamyltransferase; Glutamate Dehydrogenase; Indoles; Intestine, Small; Kidney; Kidney Diseases; Ligation; Liver; Liver Diseases; Male; Mercury Poisoning; Muscles; Mycotoxins; Myocardium; Pancreas; Pyrazines; Pyrroles; Sheep; Sheep Diseases; Urea | 1974 |
[The role of delta-aminolevulinicacid-dehydrase (ALA-D) in the erythrocytes in the study of porphyrin biosynthesis].
Topics: Erythrocytes; Hepatitis; Hepatolenticular Degeneration; Humans; Hydro-Lyases; Kidney Diseases; Lead Poisoning; Levulinic Acids; Liver Cirrhosis; Nephritis; Porphyrias; Porphyrins; Pyelonephritis; Pyrroles | 1968 |
The diagnosis of industrial lead poisoning.
Topics: Adult; Blood Cell Count; Blood Pressure Determination; Environmental Exposure; Hematocrit; Humans; Kidney Diseases; Lead; Lead Poisoning; Levulinic Acids; Male; Porphyrins; Pyrroles; Reticulocytes; Urea; Uric Acid | 1968 |